Cargando…
Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?
In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B‐cell and T‐cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after 24 months has...
Autores principales: | Labreuche, Julien, Assouan, Deborah, Durot, Eric, Tomowiak, Cecile, Roos‐Weil, Damien, Toussaint, Elise, Bijou, Fontanet, Lemal, Richard, Brion, Annie, Laribi, Kamel, Ysebaert, Loic, Duhamel, Alain, Morel, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541850/ https://www.ncbi.nlm.nih.gov/pubmed/35385885 http://dx.doi.org/10.1002/hon.2996 |
Ejemplares similares
-
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2022) -
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2020) -
Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022) -
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
por: Forgeard, Nathalie, et al.
Publicado: (2022) -
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)